

STO-CSCO Joint Symposium 2019

Cancer Immunotherapy – Fulfilling the Promise

Afternoon Session, September 20, CSCO Annual Meeting
(1-D Room, 1st Floor, Xiamen International Conference Center Hotel)

Co-Chairs:

- **LI Jin, MD**, President, *Chinese Society of Clinical Oncology (CSCO)*
- **Martin J. Murphy, DMedSc, PhD, FASCO**, Founder & Convener, *Society for Translational Oncology (STO)*, CSCO Steering Committee Member

01:30 – 02:00 Immuno-Oncology – Understanding the Differences between East and West

- **Evan W Newell, PhD**
Associate Member, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center

02:00 – 02:30 Immunotherapy in China: Challenges and Opportunities

- **LU Shun, MD, PhD**
Director General, Oncology Department, Shanghai Chest Hospital affiliated to Shanghai Jiaotong University

02:30 – 03:00 Patient Access to Cancer Immunotherapy: Health Technology Assessment (HTA) Perspective

- **Giovanni Tafuri, PhD**
Senior Scientific Officer, European Network for Health Technology Assessment (EUnetHTA)

03:00 – 03:30 Developing China's Cancer Immunotherapy Industry: Collaboration and Promise

- **Richard Wang, PhD, MBA**
Chief Executive Officer, Fosun Kite Biotechnology

03:30 – 04:00 Cell-Based Cancer Immunotherapy in Europe

- **Robert Hawkins, MA, MB, BS, PhD, FRCP**
Chief Executive Officer, Immetacyte
Honorary Professor of Medical Oncology, University of Manchester

04:00 – 04:30 Regulatory Perspective: Challenges and Opportunities for the Use of Imaging Data in Immuno-Oncology Drug Development

- **Qi Liu, PhD**
Clinical Pharmacology Team Leader, Division of Clinical Pharmacology V, Office of Clinical Pharmacology, Center for Drug Evaluation and Research (CDER), FDA

04:30 – 05:00 CAR T-Cell Therapy Landscape in the United States and China: Challenges of Sustainability and Regulation

- **GAO Jianchao, MD**
Center for Drug Evaluation, National Medical Products Administration (NMPA)